Pharmatest to exhibit and present at the AACR 2023 Annual Meeting

We will be presenting three abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 held in Orlando April 14-19.

Stop by our booth #347 to discuss more about your preclinical research needs. To schedule a meeting with our team, connect with us via email

Poster #49, section 2, April 16, 1:30 – 5:00 PM

“Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer”

We will be presenting the properties of subcutaneous and orthotopic tumor growth in two syngeneic models. Subcutaneous tumors have earned their place in drug development but adding more sophisticated models to the testing panel before entering the clinical phase should improve the success rate. There was a striking difference in the tumor growth rate in s.c. versus abdominal sites in both models. The growth was 4-5 times faster in the abdominal sites than subcutaneously, highlighting the effect of tumor specific microenvironment and giving a more relevant evaluation of the potency of the drug candidates.

Poster #2481, section 5, April 17, 1:30 – 5:00 PM

Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action

Metastasis to bone is one of the common complications associated with different types of advanced cancer. In this study, we studied the effects of zoledronic acid and denosumab on osteoclast differentiation and bone resorption activity using human CD34+ osteoclast precursor cells that were cultured on bovine bone slices in 96-well plates for 7 days in the presence of RANKL and M-CSF, allowing them to differentiate into mature osteoclasts.

This osteoclast culture system can be used for identifying new potential compounds affecting the disease process of bone metastases with different mechanisms of action.

Poster #5043, Section 19, April 18, 2023, 1:30 – 5:00 PM

“Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer” (in collaboration with Bayer AG and Aurexel Life Sciences Ltd)

In this study, we evaluated preclinical antitumor efficacy and potential beneficial combination effects of radium-223 combined with 177Lu‑PSMA‑617 in the intratibial LNCaP xenograft model mimicking progressive prostate cancer micrometastases in bone. The combination of radium-223 and 177Lu-PSMA-I&T is currently being investigated in patients with mCRPC in a phase 1/2 trial.

Learn more about our preclinical oncology services.